Corvus Pharmaceuticals, Inc. Operating Cash Flow
Corvus Pharmaceuticals, Inc. (CRVS) reported Operating Cash Flow of -$25.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$15.40M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$10.37M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$9.19M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$9.57M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$32.80M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$25.42M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$23.93M.
- Corvus Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$27.02M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$15.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$25.77M 10-Q · filed 2026-08-06 | -$34.96M derived: sum of 3 quarters · filed 2026-08-06 | -$44.53M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$10.37M 10-Q · filed 2026-05-07 | -$19.57M derived: sum of 2 quarters · filed 2026-05-07 | -$29.13M derived: sum of 3 quarters · filed 2026-05-07 | -$34.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$18.76M derived: sum of 2 quarters · filed 2026-03-12 | -$24.53M derived: sum of 3 quarters · filed 2026-08-06 | -$32.80M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$9.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$15.34M derived: sum of 2 quarters · filed 2026-08-06 | -$23.61M 10-Q · filed 2025-11-04 | -$32.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$5.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$14.04M 10-Q · filed 2026-08-06 | -$22.50M derived: sum of 3 quarters · filed 2026-08-06 | -$28.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$8.26M 10-Q · filed 2026-05-07 | -$16.73M derived: sum of 2 quarters · filed 2026-05-07 | -$23.05M derived: sum of 3 quarters · filed 2026-05-07 | -$28.53M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$8.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$14.79M derived: sum of 2 quarters · filed 2026-03-12 | -$20.27M derived: sum of 3 quarters · filed 2026-03-12 | -$25.42M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$6.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$11.80M derived: sum of 2 quarters · filed 2025-11-04 | -$16.96M 10-Q · filed 2025-11-04 | -$22.13M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | -$5.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$10.64M 10-Q · filed 2025-08-07 | -$15.80M derived: sum of 3 quarters · filed 2026-03-12 | -$21.24M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | -$5.16M 10-Q · filed 2025-05-08 | -$10.32M derived: sum of 2 quarters · filed 2026-03-12 | -$15.76M derived: sum of 3 quarters · filed 2026-03-12 | -$20.98M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$5.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$10.60M derived: sum of 2 quarters · filed 2026-03-12 | -$15.82M derived: sum of 3 quarters · filed 2026-03-12 | -$23.93M 10-K · filed 2026-03-12 |
| 2023-09-30 | -$5.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$10.66M derived: sum of 2 quarters · filed 2024-11-12 | -$18.77M 10-Q · filed 2024-11-12 | -$26.32M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-06-30 | -$5.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$13.33M 10-Q · filed 2024-08-06 | -$20.88M derived: sum of 3 quarters · filed 2025-03-25 | -$27.81M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-03-31 | -$8.11M 10-Q · filed 2024-05-07 | -$15.66M derived: sum of 2 quarters · filed 2025-03-25 | -$22.59M derived: sum of 3 quarters · filed 2025-03-25 | -$28.71M derived: sum of 4 quarters · filed 2025-03-25 |
| 2022-12-31 | -$7.55M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$14.48M derived: sum of 2 quarters · filed 2025-03-25 | -$20.60M derived: sum of 3 quarters · filed 2025-03-25 | -$27.02M 10-K · filed 2025-03-25 |
| 2022-09-30 | -$6.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$13.05M derived: sum of 2 quarters · filed 2023-11-07 | -$19.48M 10-Q · filed 2023-11-07 | -$26.33M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | -$6.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$12.55M 10-Q · filed 2023-08-08 | -$19.40M derived: sum of 3 quarters · filed 2024-03-19 | -$27.83M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | -$6.42M 10-Q · filed 2023-05-08 | -$13.28M derived: sum of 2 quarters · filed 2024-03-19 | -$21.70M derived: sum of 3 quarters · filed 2024-03-19 | -$34.35M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | -$6.86M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$15.28M derived: sum of 2 quarters · filed 2024-03-19 | -$27.93M derived: sum of 3 quarters · filed 2024-03-19 | -$36.72M 10-K · filed 2024-03-19 |
| 2021-09-30 | -$8.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$21.07M derived: sum of 2 quarters · filed 2022-11-03 | -$29.86M 10-Q · filed 2022-11-03 | -$38.07M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | -$12.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$21.43M 10-Q · filed 2022-08-08 | -$29.64M derived: sum of 3 quarters · filed 2023-03-28 | -$37.37M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | -$8.79M 10-Q · filed 2022-05-05 | -$16.99M derived: sum of 2 quarters · filed 2023-03-28 | -$24.73M derived: sum of 3 quarters · filed 2023-03-28 | -$34.21M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | -$8.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$15.94M derived: sum of 2 quarters · filed 2023-03-28 | -$25.43M derived: sum of 3 quarters · filed 2023-03-28 | -$34.78M 10-K · filed 2023-03-28 |
| 2020-09-30 | -$7.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | -$17.22M derived: sum of 2 quarters · filed 2021-11-01 | -$26.57M 10-Q · filed 2021-11-01 | -$35.08M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | -$9.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | -$18.84M 10-Q · filed 2021-08-02 | -$27.35M derived: sum of 3 quarters · filed 2022-03-10 | -$37.96M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | -$9.35M 10-Q · filed 2021-04-29 | -$17.86M derived: sum of 2 quarters · filed 2022-03-10 | -$28.47M derived: sum of 3 quarters · filed 2022-03-10 | -$37.68M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | -$8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$19.12M derived: sum of 2 quarters · filed 2022-03-10 | -$28.33M derived: sum of 3 quarters · filed 2022-03-10 | -$37.32M 10-K · filed 2022-03-10 |
| 2019-09-30 | -$10.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | -$19.82M derived: sum of 2 quarters · filed 2020-10-29 | -$28.81M 10-Q · filed 2020-10-29 | -$37.07M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | -$9.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | -$18.20M 10-Q · filed 2020-07-30 | -$26.46M derived: sum of 3 quarters · filed 2021-03-25 | -$37.26M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | -$8.99M 10-Q · filed 2020-04-30 | -$17.25M derived: sum of 2 quarters · filed 2021-03-25 | -$28.04M derived: sum of 3 quarters · filed 2021-03-25 | -$38.93M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | -$8.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$19.05M derived: sum of 2 quarters · filed 2021-03-25 | -$29.94M derived: sum of 3 quarters · filed 2021-03-25 | -$40.99M 10-K · filed 2021-03-25 |
| 2018-09-30 | -$10.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | -$21.69M derived: sum of 2 quarters · filed 2019-10-29 | -$32.73M 10-Q · filed 2019-10-29 | -$43.71M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-06-30 | -$10.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | -$21.93M 10-Q · filed 2019-08-01 | -$32.91M derived: sum of 3 quarters · filed 2020-03-09 | -$43.69M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-03-31 | -$11.04M 10-Q · filed 2019-05-09 | -$22.02M derived: sum of 2 quarters · filed 2020-03-09 | -$32.80M derived: sum of 3 quarters · filed 2020-03-09 | -$44.51M derived: sum of 4 quarters · filed 2020-03-09 |
| 2017-12-31 | -$10.98M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | -$21.75M derived: sum of 2 quarters · filed 2020-03-09 | -$33.46M derived: sum of 3 quarters · filed 2020-03-09 | -$46.21M 10-K · filed 2020-03-09 |
| 2017-09-30 | -$10.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | -$22.48M derived: sum of 2 quarters · filed 2018-11-01 | -$35.23M 10-Q · filed 2018-11-01 | -$44.64M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | -$11.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | -$24.46M 10-Q · filed 2018-08-02 | -$33.87M derived: sum of 3 quarters · filed 2019-03-07 | -$40.55M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | -$12.75M 10-Q · filed 2018-05-03 | -$22.16M derived: sum of 2 quarters · filed 2019-03-07 | -$28.84M derived: sum of 3 quarters · filed 2019-03-07 | |
| 2016-12-31 | -$9.41M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | -$16.09M derived: sum of 2 quarters · filed 2019-03-07 | -$27.86M 10-K · filed 2019-03-07 | |
| 2016-09-30 | -$6.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | -$18.45M 10-Q · filed 2017-11-02 | ||
| 2016-06-30 | -$11.77M 10-Q · filed 2017-08-03 | |||
| 2015-12-31 | -$11.33M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |